Gel-microemulsions as vaginal spermicides and intravaginal drug delivery vehicles.
There is a need for novel formulations to improve the bioavailability through the vaginal/rectal mucosa of microbicidal drug substances against sexually transmitted diseases. In addition, there is a need for more effective and less toxic vaginal spermicides. Here we review our recent discovery of novel gel-microemulsions (GM) as nontoxic, dual-function intravaginal spermicides, which can be used as delivery vehicles for lipophilic drug substances targeting sexually transmitted pathogens. We describe the formulation and biologic properties of 2 novel, submicron-particle-size GMs, GM-4 and GM-144, which were prepared from commonly available pharmaceutical excipients. These GMs comprising oil-in-water microemulsion and polymeric hydrogels were designed to solubilize lipophilic antiviral/antimicrobial agents and exhibited rapid spermicidal activity in human semen. Preclinical studies comparing the in vivo contraceptive efficacy of GM-4 and GM-144 versus nonoxynol-9-based detergent spermicide (Gynol II) in the rigorous rabbit model confirmed the potent contraceptive activity of these GMs. Unlike nonoxynol-9, repeated intravaginal applications of GM-4 and GM-144 in the rabbit vaginal irritation test were not associated with local inflammation or damage of the vaginal mucosa or epithelium. Furthermore, in short-term toxicity studies performed in mice, repetitive intravaginal application of spermicidal GM-4 and GM-144 for up to 13 weeks was not associated with any local, systemic, or reproductive toxicity. Spermicidal GMs have unprecedented potential as dual function microbicidal contraceptives to improve vaginal bioavailability of poorly soluble antimicrobial agents without causing significant vaginal damage.
D'Cruz
O J
OJ
Drug Discovery Program, Department of Reproductive Biology, Parker Hughes Institute, St. Paul, MN 55113, USA. odcruz@ih.org
Uckun
F M
FM
D000282:Administration, Intravaginal; D000818:Animals; D000890:Anti-Infective Agents / Q000008:administration & dosage; D004337:Drug Carriers; D004655:Emulsions / Q000009:adverse effects; D005260:Female; D005782:Gels / Q000009:adverse effects; D006801:Humans; D012749:Sexually Transmitted Diseases / Q000517:prevention & control; D013089:Spermatocidal Agents / Q000008:administration & dosage*
D000890:Anti-Infective Agents; D004337:Drug Carriers; D004655:Emulsions; D005782:Gels; D013089:Spermatocidal Agents